Skip to main content
Top
Published in: Endocrine 3/2011

01-06-2011 | Original Article

Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats

Authors: Weiping Sun, Yan Bi, Hua Liang, Mengyin Cai, Xiang Chen, Yanhua Zhu, Ming Li, Fen Xu, Qiuqiong Yu, Xiaoying He, Jianping Ye, Jianping Weng

Published in: Endocrine | Issue 3/2011

Login to get access

Abstract

To understand the mechanism by which early insulin therapy improves insulin sensitivity in type 2 diabetes, we investigated endoplasmic reticulum (ER) stress in the liver of type 2 diabetic rats. A high fat diet plus a low dose of streptozotocin (STZ) in Sprague–Dawley (SD) rats was implemented to create an animal model mimicking diabetes. After 3 weeks of insulin treatment, the rats were examined for insulin sensitivity and ER stress in the liver. To investigate insulin sensitivity within the liver, serine phosphorylation of IRS-1 (Ser307) and Akt (Ser473) and expression of gluconeogenic genes, PEPCK and G6Pase, were tested. Protein levels of ER stress markers, such as immunoglobulin binding protein (Bip), inositol-requiring protein 1 alpha (IRE1α), and unspliced and spliced x-box binding protein-1 (XBP-1), were determined to assess ER stress. In the diabetic (DM) group, IRS-1 phosphorylation was increased (P < 0.05), Akt phosphorylation was reduced (P < 0.05), expression of PEPCK and G6Pase was elevated (P < 0.05), and ER stress markers were up-regulated (P < 0.05) relative to the non-diabetic rats. In the insulin (INS) therapy group, all of aforementioned changes were attenuated or reversed (P < 0.05). In addition, c-Jun N-terminal kinase (JNK) activity and SREBP-1 expression were decreased (P < 0.05). Adipose tissue mass was increased (P < 0.05). These data suggest that short-term insulin therapy relieved ER stress and enhanced insulin sensitivity in the liver of diabetic rats. The mechanism is likely related to fat redistribution from liver to adipose tissue. These cellular and molecular responses may represent a mechanism for improvement of insulin sensitivity in type 2 diabetic rats by insulin therapy.
Literature
1.
go back to reference J. Weng, Y. Li, W. Xu et al., Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371, 1753–1760 (2008)PubMedCrossRef J. Weng, Y. Li, W. Xu et al., Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371, 1753–1760 (2008)PubMedCrossRef
2.
go back to reference Y. Bi, W.P. Sun, X. Chen et al., Effect of early insulin therapy on nuclear factor kappaB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats. Acta Diabetol 45, 167–178 (2008)PubMedCrossRef Y. Bi, W.P. Sun, X. Chen et al., Effect of early insulin therapy on nuclear factor kappaB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats. Acta Diabetol 45, 167–178 (2008)PubMedCrossRef
3.
go back to reference Y. Li, W. Xu, Z. Liao et al., Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27, 2597–2602 (2004)PubMedCrossRef Y. Li, W. Xu, Z. Liao et al., Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27, 2597–2602 (2004)PubMedCrossRef
4.
go back to reference M.J. Gormley, D.R. Hadden, R. Woods et al., One month’s insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal. Metabolism 35, 1029–1036 (1986)PubMedCrossRef M.J. Gormley, D.R. Hadden, R. Woods et al., One month’s insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal. Metabolism 35, 1029–1036 (1986)PubMedCrossRef
5.
go back to reference W.J. Andrews, B. Vasquez, M. Nagulesparan et al., Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33, 634–642 (1984)PubMedCrossRef W.J. Andrews, B. Vasquez, M. Nagulesparan et al., Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33, 634–642 (1984)PubMedCrossRef
6.
go back to reference W.T. Garvey, J.M. Olefsky, J. Griffin et al., The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34, 222–234 (1985)PubMedCrossRef W.T. Garvey, J.M. Olefsky, J. Griffin et al., The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34, 222–234 (1985)PubMedCrossRef
7.
go back to reference M. Laakso, M. Uusitupa, J. Takala et al., Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects. Metabolism 37, 1092–1100 (1988)PubMedCrossRef M. Laakso, M. Uusitupa, J. Takala et al., Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non-insulin-dependent diabetic subjects. Metabolism 37, 1092–1100 (1988)PubMedCrossRef
8.
go back to reference M.C. Bravi, A. Armiento, O. Laurenti et al., Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 55, 691–695 (2006)PubMedCrossRef M.C. Bravi, A. Armiento, O. Laurenti et al., Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 55, 691–695 (2006)PubMedCrossRef
9.
go back to reference H. Kaneto, Y. Nakatani, D. Kawamori et al., Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int. J. Biochem. Cell Biol. 37, 1595–1608 (2005)PubMedCrossRef H. Kaneto, Y. Nakatani, D. Kawamori et al., Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int. J. Biochem. Cell Biol. 37, 1595–1608 (2005)PubMedCrossRef
10.
go back to reference L. Juurinen, M. Tiikkainen, A.M. Hakkinen et al., Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292, E829–E835 (2007)PubMedCrossRef L. Juurinen, M. Tiikkainen, A.M. Hakkinen et al., Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292, E829–E835 (2007)PubMedCrossRef
11.
go back to reference D. LeRoith, V. Fonseca, Vinik A Metabolic memory in diabetes—focus on insulin. Diabetes Metab. Res. Rev. 21, 85–90 (2005)PubMedCrossRef D. LeRoith, V. Fonseca, Vinik A Metabolic memory in diabetes—focus on insulin. Diabetes Metab. Res. Rev. 21, 85–90 (2005)PubMedCrossRef
12.
go back to reference U. Ozcan, Q. Cao, E. Yilmaz et al., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457–461 (2004)PubMedCrossRef U. Ozcan, Q. Cao, E. Yilmaz et al., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457–461 (2004)PubMedCrossRef
13.
go back to reference A. Garg, A. Misra, Hepatic steatosis, insulin resistance, and adipose tissue disorders. J. Clin. Endocrinol. Metab. 87, 3019–3022 (2002)PubMedCrossRef A. Garg, A. Misra, Hepatic steatosis, insulin resistance, and adipose tissue disorders. J. Clin. Endocrinol. Metab. 87, 3019–3022 (2002)PubMedCrossRef
14.
go back to reference A. Seppala-Lindroos, S. Vehkavaara, A.M. Hakkinen et al., Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023–3028 (2002)PubMedCrossRef A. Seppala-Lindroos, S. Vehkavaara, A.M. Hakkinen et al., Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023–3028 (2002)PubMedCrossRef
15.
go back to reference Y. Bi, M. Cai, H. Liang et al., Increased carnitine palmitoyl transferase 1 expression and decreased sterol regulatory element-binding protein 1c expression are associated with reduced intramuscular triglyceride accumulation after insulin therapy in high-fat-diet and streptozotocin-induced diabetic rats. Metabolism 58, 779–786 (2009)PubMedCrossRef Y. Bi, M. Cai, H. Liang et al., Increased carnitine palmitoyl transferase 1 expression and decreased sterol regulatory element-binding protein 1c expression are associated with reduced intramuscular triglyceride accumulation after insulin therapy in high-fat-diet and streptozotocin-induced diabetic rats. Metabolism 58, 779–786 (2009)PubMedCrossRef
16.
go back to reference M.J. Reed, K. Meszaros, L.J. Entes et al., A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390–1394 (2000)PubMedCrossRef M.J. Reed, K. Meszaros, L.J. Entes et al., A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390–1394 (2000)PubMedCrossRef
17.
go back to reference K. Srinivasan, B. Viswanad, L. Asrat et al., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313–320 (2005)PubMedCrossRef K. Srinivasan, B. Viswanad, L. Asrat et al., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313–320 (2005)PubMedCrossRef
18.
go back to reference M. Sugano, H. Yamato, T. Hayashi et al., High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr. Metab. Cardiovasc. Dis. 16, 477–484 (2006)PubMedCrossRef M. Sugano, H. Yamato, T. Hayashi et al., High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr. Metab. Cardiovasc. Dis. 16, 477–484 (2006)PubMedCrossRef
19.
go back to reference K. Sahin, M. Onderci, M. Tuzcu et al., Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 56, 1233–1240 (2007)PubMedCrossRef K. Sahin, M. Onderci, M. Tuzcu et al., Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 56, 1233–1240 (2007)PubMedCrossRef
20.
go back to reference J.E. Pessin, A.R. Saltiel, Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 106, 165–169 (2000)PubMedCrossRef J.E. Pessin, A.R. Saltiel, Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 106, 165–169 (2000)PubMedCrossRef
21.
go back to reference R.W. Hanson, L. Reshef, Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 66, 581–611 (1997)PubMedCrossRef R.W. Hanson, L. Reshef, Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 66, 581–611 (1997)PubMedCrossRef
22.
go back to reference J. Hirosumi, G. Tuncman, L. Chang et al., A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002)PubMedCrossRef J. Hirosumi, G. Tuncman, L. Chang et al., A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002)PubMedCrossRef
23.
go back to reference A.S. Lee, The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 35, 373–381 (2005)PubMedCrossRef A.S. Lee, The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 35, 373–381 (2005)PubMedCrossRef
24.
go back to reference J.D. Horton, J.L. Goldstein, M.S. Brown, SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002)PubMed J.D. Horton, J.L. Goldstein, M.S. Brown, SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002)PubMed
25.
go back to reference G. Boden, X. Duan, C. Homko et al., Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 57, 2438–2444 (2008)PubMedCrossRef G. Boden, X. Duan, C. Homko et al., Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 57, 2438–2444 (2008)PubMedCrossRef
26.
go back to reference M.S. Brown, J.L. Goldstein, A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96, 11041–11048 (1999)PubMedCrossRef M.S. Brown, J.L. Goldstein, A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96, 11041–11048 (1999)PubMedCrossRef
27.
go back to reference M.S. Brown, J.L. Goldstein, The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997)PubMedCrossRef M.S. Brown, J.L. Goldstein, The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997)PubMedCrossRef
28.
go back to reference M.S. Brown, J. Ye, R.B. Rawson et al., Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391–398 (2000)PubMedCrossRef M.S. Brown, J. Ye, R.B. Rawson et al., Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391–398 (2000)PubMedCrossRef
29.
go back to reference H.L. Kammoun, H. Chabanon, I. Hainault et al., GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest. 119, 1201–1215 (2009)PubMedCrossRef H.L. Kammoun, H. Chabanon, I. Hainault et al., GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest. 119, 1201–1215 (2009)PubMedCrossRef
30.
go back to reference T. Pratipanawatr, K. Cusi, P. Ngo et al., Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 51, 462–468 (2002)PubMedCrossRef T. Pratipanawatr, K. Cusi, P. Ngo et al., Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 51, 462–468 (2002)PubMedCrossRef
31.
go back to reference S. Matthaei, M. Stumvoll, M. Kellerer et al., Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. 21, 585–618 (2000)PubMedCrossRef S. Matthaei, M. Stumvoll, M. Kellerer et al., Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. 21, 585–618 (2000)PubMedCrossRef
32.
go back to reference U. Ozcan, E. Yilmaz, L. Ozcan et al., Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137–1140 (2006)PubMedCrossRef U. Ozcan, E. Yilmaz, L. Ozcan et al., Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137–1140 (2006)PubMedCrossRef
33.
go back to reference S.K. Das, W.S. Chu, A.K. Mondal et al., Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. Am. J. Physiol. Endocrinol. Metab. 295, E393–E400 (2008)PubMedCrossRef S.K. Das, W.S. Chu, A.K. Mondal et al., Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. Am. J. Physiol. Endocrinol. Metab. 295, E393–E400 (2008)PubMedCrossRef
34.
go back to reference N.K. Sharma, S.K. Das, A.K. Mondal et al., Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J. Clin. Endocrinol. Metab. 93, 4532–4541 (2008)PubMedCrossRef N.K. Sharma, S.K. Das, A.K. Mondal et al., Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J. Clin. Endocrinol. Metab. 93, 4532–4541 (2008)PubMedCrossRef
35.
go back to reference G.J. Hausman, Richardson RL Adipose tissue angiogenesis. J. Anim. Sci. 82, 925–934 (2004)PubMed G.J. Hausman, Richardson RL Adipose tissue angiogenesis. J. Anim. Sci. 82, 925–934 (2004)PubMed
36.
37.
go back to reference J. Ye, Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. (Lond) 33, 54–66 (2009)CrossRef J. Ye, Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. (Lond) 33, 54–66 (2009)CrossRef
38.
go back to reference J. Ye, Z. Gao, J. Yin et al., Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293, E1118–E1128 (2007)PubMedCrossRef J. Ye, Z. Gao, J. Yin et al., Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293, E1118–E1128 (2007)PubMedCrossRef
39.
go back to reference J. Yin, Z. Gao, Q. He et al., Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 296, E333–E342 (2009)PubMedCrossRef J. Yin, Z. Gao, Q. He et al., Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 296, E333–E342 (2009)PubMedCrossRef
40.
go back to reference C. Pang, Z. Gao, J. Yin et al., Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity. Am. J. Physiol. Endocrinol. Metab. 295, E313–E322 (2008)PubMedCrossRef C. Pang, Z. Gao, J. Yin et al., Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity. Am. J. Physiol. Endocrinol. Metab. 295, E313–E322 (2008)PubMedCrossRef
41.
go back to reference H. Shimano, N. Yahagi, M. Amemiya-Kudo et al., Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274, 35832–35839 (1999)PubMedCrossRef H. Shimano, N. Yahagi, M. Amemiya-Kudo et al., Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274, 35832–35839 (1999)PubMedCrossRef
42.
go back to reference M. Foretz, C. Guichard, P. Ferre et al., Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. USA 96, 12737–12742 (1999)PubMedCrossRef M. Foretz, C. Guichard, P. Ferre et al., Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. USA 96, 12737–12742 (1999)PubMedCrossRef
Metadata
Title
Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats
Authors
Weiping Sun
Yan Bi
Hua Liang
Mengyin Cai
Xiang Chen
Yanhua Zhu
Ming Li
Fen Xu
Qiuqiong Yu
Xiaoying He
Jianping Ye
Jianping Weng
Publication date
01-06-2011
Publisher
Springer US
Published in
Endocrine / Issue 3/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9429-y

Other articles of this Issue 3/2011

Endocrine 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.